Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.46 |
| ▸ | MTOR | P42345 | 2/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.45 |
| ▸ | RAF1 | P04049 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5658815 | 0.88 | TRPV1 (0.55) | TRPV1MAPK1MTORNAMPTMAPT | |
| SCHEMBL5659169 | 0.86 | TRPV1 (0.68) | TRPV1KMT2APOLBALDH1A1LMNA | |
| SCHEMBL5661578 | 0.80 | TRPV1 (0.71) | TRPV1MTORNAMPT | |
| SCHEMBL6686578 | 0.76 | TRPV1 (0.68) | TRPV1KMT2ARAF1ALDH1A1 | |
| SCHEMBL5661128 | 0.76 | TRPV1 (0.65) | TRPV1NAMPTALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL14014096 | 0.74 | NPC1 (0.52) | TRPV1KMT2AMTORNAMPTL3MBTL1 | |
| SCHEMBL5657810 | 0.74 | MAPK1 (0.53) | TRPV1MAPK1MTORNAMPTATG4B | |
| SCHEMBL5658216 | 0.74 | TRPV1 (0.72) | TRPV1KMT2AMAPK1ALDH1A1 | |
| SCHEMBL5657625 | 0.74 | TRPV1 (0.68) | TRPV1KMT2AALDH1A1 | |
| SCHEMBL5659710 | 0.73 | TRPV1 (0.51) | TRPV1MAPK1ATG4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7285563-B2 | Heteroaromatic urea derivatives as VR-1 receptor modulators for treating pain | MERCK SHARP & DOHME LTD. (GB) | 2007-10-23 | — | — | US | disclosed |
| US-20050107388-A1 | Heteroaromatic urea derivatives as vr-1receptor modulators for treating pain | MERCK SHARP & DOHME LTD. (GB) | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107388-A1 | Heteroaromatic urea derivatives as vr-1receptor modulators for treating pain | ARRB1, OPRL1, CNR1 | TRPV1 37/4885KMT2A 4465/4885MAPK1 1633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.